INTRODUCTION
============

Li-Fraumeni syndrome (LFS, OMIM \#151623) is an autosomal dominant cancer predisposition syndrome caused by a germline mutation in the *TP53* tumor suppressor gene \[[@B1][@B2]\]. LFS is characterized by an early onset of tumors and a lifetime risk of developing multiple primary tumors, with individuals likely to develop osteosarcoma, soft tissue sarcoma, pre-menopausal breast cancer, brain tumors, adrenocortical carcinoma (ACC), and acute leukemia \[[@B1]\]. These core component tumors comprise \~70% of LFS-related tumors. In addition, there is growing evidence that a wide spectrum of cancers, including lung cancers or stomach cancers, is associated with LFS \[[@B3][@B4][@B5][@B6]\].

LFS diagnosis can be confirmed by a genetic mutation in *TP53*. According to the largest *TP53* mutation database, the International Agency for Research on Cancer (IARC) database (version R18, April 2016, <http://p53.iarc.fr/>), over 700 germline mutations have been described to date \[[@B7]\]. Although most mu-tations are scattered throughout the gene, several hotspots such as codons 125, 158, 175, 196, 213, 220, 245, 248, 273, 282, and 337 have been reported \[[@B7][@B8]\]. Furthermore, the spectrum of LFS-related *TP53* mutations can be categorized into two groups: (1) gain of function mutations (missense mutations) conferring a dominant-negative effect or promoting an oncogenic effect and (2) loss of function mutations such as nonsense and frameshift mutations \[[@B9][@B10]\]. A previous study reported that missense mutations rather than nonsense or frameshift mutations are associated with an earlier onset of cancer \[[@B8]\].

Although the IARC database provided essential information pertaining to the mutation distribution and cancer spectrum in LFS, the majority of data originated from Caucasian populations \[[@B7]\]. Currently, little is known about the mutation and tumor spectrum of Korean patients with LFS. Owing to the rarity of LFS, few case reports of Korean patients have been published \[[@B11][@B12][@B13][@B14][@B15][@B16]\]. However, the data presented in these case reports were too limited to assess the mutation spectrum in Korean patients with LFS. We aimed to evaluate the mutation features and clinical characteristics, including the tumor spectrum, of Korean patients with LFS.

METHODS
=======

1. Study subjects
-----------------

The Institutional Review Board of the Samsung Medical Center in Korea approved this study. This retrospective review was exempt from the requirement for informed consent. *TP53* mutation was screened in 89 unrelated individuals at the Samsung Medical Center from 2003 to 2015. Among them, eight patients were selected as mutation carriers (9%, 8/89). Six additional mutation carriers were identified from case reports published in the literature \[[@B11][@B12][@B13][@B14][@B15][@B16]\]. We collected information on the age at the first tumor onset, sex, familial cancer history, and tumor spectrum from the 14 mutation-positive cases.

2. *TP53* mutation analysis
---------------------------

All 11 exons and their flanking intron regions of *TP53* were amplified by PCR using primer pairs designed with the Primer3 software in samples from 85 individuals. In the remaining four individuals, exons 4-9 and their flanking regions were targeted. Sanger sequencing was performed by using the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) and an ABI Prism 3100 Genetic Analyzer (Applied Biosystems). The mutation status was assessed by using the Human Genome Mutation Database (HGMD, professional version 2014.01) and IARC *TP53* database (version R18, April 2016, <http://p53.iarc.fr/>) \[[@B7]\]. The \"A\" of the ATG translation initiation codon is described as position number 1 in *TP53* (NM_000546.4). Mutation group and domain were based on previously reported structural data and the Pfam database, respectively \[[@B8][@B17]\].

RESULTS
=======

1. Spectrum of germline *TP53* mutations
----------------------------------------

The mutations consisted of seven known mutations and two novel mutations in 14 unrelated Korean patients with 30 tumors. Six missense mutations (11/14, 79%), two frameshift deletions (2/14, 14%), and one nonsense mutation (1/14, 7%) were detected ([Table 1](#T1){ref-type="table"}). All mutations were distributed among exons 3 to 8; the DNA-binding domain (n=10) and transactivation domain (n=3) ([Table 1](#T1){ref-type="table"}). The most common mutation locations were exons 8 (n=5), 5 (n=3), and 3 (n=3) in *TP53*. The recurrent mutations were located at codons 31 (n=2; p.Val31Ile), 175 (n=3; p.Arg175His), and 273 \[n=4; p.Arg273His (n=3), and p.Arg273Cys (n=1)\] in *TP53* ([Fig. 1](#F1){ref-type="fig"}). Two novel frameshift mutations (p.Pro98Leufs^\*^25 and p.Pro27Leufs^\*^17) were identified ([Table 1](#T1){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}).

2. Clinical characteristics of Korean *TP53* mutation carriers
--------------------------------------------------------------

The *TP53* mutation carriers included three males and 11 females (male to female ratio of 0.3:1). Clinical criteria were fulfilled in 11 patients, with the exception of three patients for whom familial cancer history was not available ([Table 1](#T1){ref-type="table"}). The median age at the first tumor manifestation was 25 yr, regardless of the mutation type.

A diverse spectrum of tumors was detected, including breast cancer (n=6), osteosarcoma/rhabdomyosarcoma (n=4/n=1), brain tumor (n=4), leukemia (n=2), stomach cancer (n=2), thyroid cancer (n=2), lung cancer (n=2), skin cancer (n=2), nasal cavity cancer (n=1), and ACC (n=1) ([Table 1](#T1){ref-type="table"}). Twelve patients (86%) had at least one of the core spectrum cancers (breast cancer, brain tumors, osteosarcoma, rhabdomyosarcoma, and ACC) ([Table 1](#T1){ref-type="table"}). Ten patients (71%) developed multiple primary tumors (range of 1-5). Therapy-related neoplasm was observed in three patients (Patients 1, 3, and 6) ([Table 1](#T1){ref-type="table"}). Among them, one patient (Patient 3) treated with radiation therapy was positive for chromosomal breakage analysis.

One novel mutation, p.Pro98Leufs^\*^25 was observed in patient 6, who was treated for ACC (at the age of 1 yr) and later developed osteosarcoma (4 yr), brain cancer (4 yr), and therapy-related neoplasm (10 yr) ([Table 1](#T1){ref-type="table"}). The other novel mutation, p.Pro27Leufs^\*^17 was identified in patient 7 ([Table 1](#T1){ref-type="table"}). After the age of 28 yr, five primary tumors developed, including left breast cancer (28 yr), neurofibroma (33 yr), right breast cancer (38 yr), right nasal cavity squamous cell carcinoma (38 yr), and EGFR-mutated (p.Leu858Arg) lung adenocarcinoma (43 yr) in patient 7 ([Table 1](#T1){ref-type="table"}). The bilateral breast cancers of patient 7 were positive for hormone receptors (estrogen and progesterone) and ERBB2 (formerly HER2/neu) while negative for *BRCA1* and *BRCA2* mutations.

DISCUSSION
==========

In this study, we investigated the mutation and tumor spectrums of Korean patients with LFS. Nine different mutations, including seven known mutations and two novel mutations, were identified in 14 unrelated patients. The codon and exon distribution of some mutations (especially codons 175 and 273) in Korean patients was similar to that in Caucasians. A notable exception was codon 337 (p.Arg337His), which was the previously reported founder mutation in Brazilian patients \[[@B18]\]. The mutation of p.Arg337His has been reported to be the most common mutation in the IARC database, but it was not identified in the Korean patients analyzed in this study.

Furthermore, missense mutations located at the loop, which were demonstrated to bind to the minor groove of DNA (L2: codons 164 to 194, L3: codons 237 to 250) and major groove of DNA (L1: codons 115 to 135, S2-S2-H2 motif: codons 273 to 286), were associated with brain cancer and ACC, respectively \[[@B8]\]. Here, we noted that the mutations of two brain cancer carriers and four breast cancer carriers were located at loop L2 and L3. However, no association was evident between tumor spectrum and mutation location, owing to the limited number of cases.

This study reported two novel frameshift mutations located at exons 3 and 4. The mutation locations and types were not present in the IARC database. The majority of previously reported mutations are missense mutations. In addition, previously reported mutations have been located mainly within exons 5-8 that encode the DNA-binding region. Despite the limited number of cases, identification of these frameshift mutations provides further insights into the *TP53* mutation spectrum from Korean patients.

The predominance of women among Korean patients was not necessarily associated with breast cancer. A previous study reported a significant gender difference, possibly due to the high incidence of breast cancer among women with LFS \[[@B19]\]. However, in this study, the predominance of women was observed for a variety of tumors, including osteosarcoma and brain tumors as well as breast cancer.

There was no significant difference in age at the first tumor diagnosis between mutation types. A previous study reported that missense variants appear to be associated with an earlier onset of cancer \[[@B8]\]. However, this study demonstrated that missense mutations (e.g., p.Val31Ile) were identified in patients with a late-onset of cancer, while frameshift mutations (e.g. p.Pro98Leufs^\*^25) were identified in patients with an early-onset of cancer. The age at tumor onset in *TP53* mutation carriers could be influenced by genetic modifiers such as SNP309 (T\>G), rs2279744 in *MDM2* as well as PIN3 in *TP53*, together with environmental factors \[[@B20][@B21]\]. Moreover, this might be possibly explained by variable expressivity.

There was a considerable heterogeneity in the relationship between *TP53* mutations and tumor spectrum. Of note, breast cancer (n=6) was the most common tumor in Korean patients, followed by osteosarcoma/rhabdomyosarcoma (n=5), brain (n=4), and others. Our findings revealed that non-core tumors such as stomach cancer (n=2), lung cancer (n=2), and thyroid cancer (n=2) were recurrently present in Korean patients. A recent study reported that stomach cancer is more frequently detected in Asian patients compared with Caucasian patients \[[@B22]\]. This suggested differences in the tumor spectrum of LFS between Caucasian and Asian patients \[[@B22]\].

Previous studies reported that, when *BRCA* mutations are not identified in patients with breast cancer diagnosed before 30 yr, the likelihood of having a *TP53* mutation is estimated to be 4-8% \[[@B19][@B23][@B24]\]. The likelihood could increase with a family history of LFS-related cancers, personal history of a breast cancer positive for hormone receptors, and/or ERBB2, or additional LFS-related cancers \[[@B24][@B25]\]. This is in agreement with the findings from patient 7 with bilateral breast cancers.

Lastly, we reported patients with *EGFR*-mutated (p.Leu858Arg) lung adenocarcinoma (in patient 7) as well as therapy-related neoplasm. To date, little data on *EGFR*-mutated lung cancer in the context of LFS have been published \[[@B5][@B6]\]. It is assumed that patient 7 had a germline *TP53* mutation (p.Pro27Leufs^\*^17) as the first genetic hit and a somatic *EGFR* mutation (p.Leu858Arg) as the second hit.

This study had several limitations. This study was performed by retrospective review in a single institution. The small number of patients as well as incomplete information might have had an impact on the results. In addition, we did not compare clinical data between *TP53* mutation-positive and -negative cases in the current study. Lastly, we did not consider genetic modifiers and environmental factors that influence the clinical phenotype. Despite these limitations, it is important that these are the first data from the largest case series of Korean patients with LFS.

In summary, this study provides the mutation features and tumor spectrum of Korean patients with LFS. There was a considerable heterogeneity in *TP53* mutations and tumor spectrum among Korean patients. This study suggests shared and different features of LFS between Caucasian and Korean patients. Further large studies are warranted to stratify the clinical management and to establish surveillance strategies specific for Korean patients with LFS.
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![Frequency distribution of *TP53* germline mutations by codon. (A) Data reproduced from the International Agency for Research on Cancer (IARC) *TP53* database (version R18, April 2016, <http://p53.iarc.fr/>) \[[@B7]\]. (B) Data from Korean patients with Li-Fraumeni syndrome. Figures above the vertical line represent the codon locations of the mutations.](alm-36-463-g001){#F1}

![Sequence chromatogram of two novel frameshift mutations in *TP53*. (A) Heterozygous mutation of c.293delC (p.Pro98Leufs^\*^25) identified in patient 6, who was treated for adrenocortical carcinoma, osteosarcoma, brain cancer, and therapy-related neoplasm. (B) Heterozygous mutation of c.78delT (p.Pro27Leufs^\*^17) identified in patient 7 with multiple primary tumors comprising left breast cancer (28 yr), neurofibroma (33 yr), right breast cancer (38 yr), right nasal cavity squamous cell carcinoma (38 yr), and lung adenocarcinoma (43 yr). Forward and reverse sequences are shown at the top and bottom, respectively.](alm-36-463-g002){#F2}

###### Clinical and *TP53* mutation data of the 14 Korean patients with Li-Fraumeni syndrome

![](alm-36-463-i001)

  Patient   Age^\*^   Sex   Tumor type (age at diagnosis)^†^                           Criteria   Exon   Domain            Group^\*\*^      NT alteration     Mutation type   AA alteration        HGMD           References
  --------- --------- ----- ---------------------------------------------------------- ---------- ------ ----------------- ---------------- ----------------- --------------- -------------------- -------------- ------------
  1         7         F     Br (7), Breast (23), Der (35), Leu (35)^‡^                 Chompret   5      DNA binding       L2               **c.524G \> A**   missense        **p.Arg175His**      **CM951224**   This study
  2         NA        F     Os (NA)                                                    NA         5      DNA binding       L2               **c.524G \> A**   missense        **p.Arg175His**      **CM951224**   This study
  3         NA        F     Os (NA), Leu^‡,§^                                          NA         8      DNA binding       S2-S2-H2 motif   **c.818G \> A**   missense        **p.Arg273His**      **CM920677**   This study
  4         45        F     Thy (45)^∥^, Lm (47)                                       NA         3      Transactivation   NA               **c.91G \> A**    missense        **p.Val31Ile**       **CM074603**   This study
  5         NA        F     Leu (NA), Breast (NA), Thy (NA)                            Chompret   8      DNA biding        S2-S2-H2 motif   c.817C \> T       missense        p.Arg273Cys          CM951233       This study
  6         1         F     ACC (1), Os, (4), Br (4), Leu (10)^‡^                      Chompret   4      NA                NA               c.293delC         frameshift      p.Pro98Leufs^\*^25   novel          This study
  7         28        F     Breast (28,38)^¶^, Nf (33), Nasal cavity (38), Lung (43)   Chompret   3      Transactivation   NA               c.78delT          frameshift      p.Pro27Leufs^\*^17   novel          This study
  8         26        M     St (26), Br (26)                                           LFL        3      Transactivation   NA               **c.91G \> A**    missense        **p.Val31Ile**       **CM074603**   This study
  9         25        F     Breast (25), Lm (25)                                       LFL        7      DNA binding       L3               c.742C \> T       missense        p.Arg248Trp          CM900211       \[[@B11]\]
  10        38        M     St (38)                                                    LFS        8      DNA binding       NA               c.859G \> T       nonsense        p.Glu287^\*^         CM044948       \[[@B12]\]
  11        24        F     Breast (25), Br (25)                                       LFL        5      DNA binding       L2               **c.524G \> A**   missense        **p.Arg175His**      **CM951224**   \[[@B13]\]
  12        2         M     Rhabdomyosarcoma (2), Br (4)                               LFS        8      DNA binding       S2-S2-H2 motif   **c.818G \> A**   missense        **p.Arg273His**      **CM920677**   \[[@B14]\]
  13        47        F     Breast (47)                                                LFL        6      DNA binding       L2               c.566C \> T       missense        p.Ala189Val          CM031755       \[[@B15]\]
  14        17        F     Os (17), Lung (17)                                         LFL        8      DNA binding       S2-S2-H2 motif   **c.818G \> A**   missense        **p.Arg273His**      **CM920677**   \[[@B16]\]

The reference sequence of *TP53* was NM_000546.4. Recurrent mutations are in bold. All mutations were heterozygous.

^\*^Age at first tumor diagnosis; ^†^In the order of tumor diagnosis; ^‡^Therapy-related myeloid neoplasm; §positive for chromosomal breakage test; ^∥^*BRAF* V600E mutation positive case; ¶*BRCA 1* and *BRCA 2* mutation negative and positive for hormone receptors (estrogen and progesterone) and ERBB2 (formerly HER2/neu); ^\*\*^Based on structural data from \[[@B8][@B17]\].

Abbreviations: NT, nucleotide; AA, Amino acid; LFS, Li-Fraumeni syndrome; LFL, Li-Fraumeni syndrome like; NA, not applicable, Br; brain; Der, dermatofibrosarcoma; Leu, leukemia; Os, Osteosarcoma; Thy, thyroid carcinoma; Lm, leiomyoma; ACC, adrenocortical carcinoma; Nf, neurofibroma; St, stomach; HGMD, Human Genome Mutation Database.
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